Talphera Inc
TLPH0.404USD
+0.001+0.30%
Market hours （ET）Quotes delayed by 15 min
6.90MMarket Cap
LossP/E TTM
More Details of Talphera Inc Company
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
Company Info
Ticker SymbolTLPH
Company nameTalphera Inc
IPO dateFeb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
Number of employees13
Security typeOrdinary Share
Fiscal year-endFeb 11
Address1850 Gateway Drive
CitySAN MATEO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94404
Phone16502163500
Websitehttps://talphera.com/
Ticker SymbolTLPH
IPO dateFeb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 5
Currency: USDUpdated: Wed, Mar 5
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
Shareholder Types
Shareholders
Proportion
Hedge Fund
25.46%
Investment Advisor
4.28%
Individual Investor
2.62%
Investment Advisor/Hedge Fund
1.06%
Research Firm
0.45%
Venture Capital
0.07%
Other
66.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
79
6.96M
33.93%
-504.17K
2025Q1
82
6.66M
34.60%
-832.94K
2024Q4
84
5.24M
30.79%
-2.31M
2024Q3
100
5.33M
31.39%
-2.35M
2024Q2
109
5.51M
32.40%
-2.29M
2024Q1
113
5.56M
32.76%
-881.00K
2023Q4
117
5.91M
35.12%
-445.19K
2023Q3
127
7.03M
43.10%
+3.84M
2023Q2
136
1.17M
10.69%
-920.00K
2023Q1
169
1.22M
11.24%
-974.29K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosalind Advisors, Inc.
2.00M
9.77%
+1.39M
+226.41%
Mar 31, 2025
Nantahala Capital Management, LLC
1.99M
9.72%
--
--
Apr 25, 2025
Armistice Capital LLC
890.35K
4.34%
-661.26K
-42.62%
Dec 31, 2023
Bleichroeder LP
426.62K
2.08%
+426.62K
--
Mar 31, 2025
Angotti Vincent J
367.85K
1.79%
+265.56K
+259.62%
Apr 25, 2025
Rock Springs Capital Management LP
316.46K
1.54%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
237.53K
1.16%
-3.44K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
165.61K
0.81%
+2.40K
+1.47%
Mar 31, 2025
Values First Advisors, Inc.
97.32K
0.47%
+771.00
+0.80%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
91.55K
0.45%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Date
Type
Ratio
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
